IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Martin Currie Ltd.

Martin Currie Ltd. lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 27.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 72,943 shares of the company's stock after selling 27,481 shares during the period. IDEXX Laboratories accounts for 1.1% of Martin Currie Ltd.'s investment portfolio, making the stock its 28th biggest position. Martin Currie Ltd. owned about 0.09% of IDEXX Laboratories worth $30,158,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in IDXX. FSA Wealth Management LLC acquired a new position in IDEXX Laboratories during the third quarter valued at approximately $25,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories in the 4th quarter worth $30,000. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories in the 4th quarter valued at about $31,000. Kestra Investment Management LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $38,000. Finally, Crews Bank & Trust acquired a new stake in IDEXX Laboratories in the fourth quarter valued at $41,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on IDXX. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Tuesday, March 25th. Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Piper Sandler raised their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Leerink Partnrs raised shares of IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Finally, Bank of America raised their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $533.75.

Remove Ads

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Performance

IDXX traded down $1.38 during trading hours on Tuesday, hitting $418.57. The company's stock had a trading volume of 518,227 shares, compared to its average volume of 584,144. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The company has a 50-day simple moving average of $437.08 and a 200 day simple moving average of $442.03. The firm has a market capitalization of $33.93 billion, a PE ratio of 39.23, a PEG ratio of 3.41 and a beta of 1.39.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.